Since niraparib was used in our previous studies, which revealed that the inhibition of PARP1-dependent PARylation induces TET-mediated DNA hydroxymethylation (Tolić et al., 2022), we additionally used niraparib in this study for the improvement in sensitivity to cisplatin in NSCLC cells. Here, PARP1 is linked to non-small cell lung carcinoma.